Abstract 1685P
Background
Family caregivers play a vital role in cancer care, yet their effective integration, needs assessment, and support in German outpatient settings require further examination. This qualitative study explores family caregivers' experiences, preferences, and integration challenges, employing a unique dyadic approach to analyze patient-caregiver dynamics and incorporating oncologists' perspectives on effective caregiver integration. It also suggests areas of potential integration of innovative technologies to address these challenges.
Methods
The study uses a reflexive thematic analysis of qualitative semi-structured interviews with 15 patient-caregiver dyads involving advanced cancer patients with solid tumours and three oncologists at a German outpatient cancer centre.
Results
Three interconnected themes emerged: 1) The multifaceted impact of illness on patient-caregiver dyads, emphasizing the significance of dyadic support and incongruence; 2) Communication with physicians and understanding of healthcare Information, stressing the need for tailored prognostic communication, and considering health literacy aspects; 3) Navigating healthcare services and psychosocial support, underlining the importance of a regular needs and distress evaluation, providing personalized support in the form of a referral and proactive guidance upon cancer diagnosis.
Conclusions
The study's findings have practical implications for healthcare practice and policy. Healthcare systems should adopt a more caregiver-inclusive approach that provides proactive psychosocial support at the beginning of the cancer journey, and tailored communication with healthcare professionals. This approach could include developing and implementing targeted digital tools that allow automated needs evaluation and incorporation of referrals for specialized support programs for cancer caregivers. The future investigation and implementation of such innovative technologies is important, as they have the potential to reduce the caregiving burden and significantly enhance the overall quality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Rose: Other, Institutional, Leadership Role: Head of Promis National Center Germany. All other authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11